William Pickering
Stock Analyst at Bernstein
(3.18)
# 2,501
Out of 4,520 analysts
216
Total ratings
54.6%
Success rate
3.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Pickering
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Rated: Hold | $35 → $46 | $74.30 | -38.09% | 9 | May 13, 2026 | |
| NTLA Intellia Therapeutics | Rated: Hold | $13 → $17 | $11.38 | +49.45% | 14 | May 13, 2026 | |
| CRSP CRISPR Therapeutics AG | Rated: Hold | $50 → $56 | $47.78 | +17.20% | 9 | May 13, 2026 | |
| BEAM Beam Therapeutics | Rated: Buy | $40 → $39 | $27.53 | +41.66% | 18 | May 13, 2026 | |
| DYN Dyne Therapeutics | Rated: Hold | $23 → $24 | $23.74 | +1.10% | 7 | May 13, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $100 → $114 | $81.38 | +40.08% | 4 | May 8, 2026 | |
| BMRN BioMarin Pharmaceutical | Rated: Buy | $94 → $82 | $59.59 | +37.61% | 21 | May 5, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $577 → $572 | $485.65 | +17.78% | 30 | May 5, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $451 → $447 | $267.47 | +67.12% | 20 | May 1, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Hold | $3.85 | $1.79 | +115.08% | 8 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $916 → $921 | $676.69 | +36.10% | 25 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 | $17.22 | +16.14% | 5 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $28 | $40.26 | -30.45% | 1 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $35 | $34.51 | +1.42% | 1 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $157 → $201 | $205.99 | -2.42% | 10 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $65 → $89 | $54.39 | +63.63% | 22 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $34 → $9 | $15.44 | -41.71% | 12 | Nov 6, 2025 |
Arrowhead Pharmaceuticals
May 13, 2026
Rated: Hold
Price Target: $35 → $46
Current: $74.30
Upside: -38.09%
Intellia Therapeutics
May 13, 2026
Rated: Hold
Price Target: $13 → $17
Current: $11.38
Upside: +49.45%
CRISPR Therapeutics AG
May 13, 2026
Rated: Hold
Price Target: $50 → $56
Current: $47.78
Upside: +17.20%
Beam Therapeutics
May 13, 2026
Rated: Buy
Price Target: $40 → $39
Current: $27.53
Upside: +41.66%
Dyne Therapeutics
May 13, 2026
Rated: Hold
Price Target: $23 → $24
Current: $23.74
Upside: +1.10%
BridgeBio Pharma
May 8, 2026
Reiterated: Buy
Price Target: $100 → $114
Current: $81.38
Upside: +40.08%
BioMarin Pharmaceutical
May 5, 2026
Rated: Buy
Price Target: $94 → $82
Current: $59.59
Upside: +37.61%
Vertex Pharmaceuticals
May 5, 2026
Maintained: Buy
Price Target: $577 → $572
Current: $485.65
Upside: +17.78%
Alnylam Pharmaceuticals
May 1, 2026
Reiterated: Buy
Price Target: $451 → $447
Current: $267.47
Upside: +67.12%
Allogene Therapeutics
Apr 14, 2026
Maintained: Hold
Price Target: $3.85
Current: $1.79
Upside: +115.08%
Apr 8, 2026
Maintained: Buy
Price Target: $916 → $921
Current: $676.69
Upside: +36.10%
Mar 25, 2026
Maintained: Hold
Price Target: $20
Current: $17.22
Upside: +16.14%
Mar 20, 2026
Initiated Coverage: Hold
Price Target: $28
Current: $40.26
Upside: -30.45%
Mar 20, 2026
Initiated Coverage: Buy
Price Target: $35
Current: $34.51
Upside: +1.42%
Feb 6, 2026
Maintained: Hold
Price Target: $157 → $201
Current: $205.99
Upside: -2.42%
Jan 13, 2026
Maintained: Hold
Price Target: $65 → $89
Current: $54.39
Upside: +63.63%
Nov 6, 2025
Downgraded: Hold
Price Target: $34 → $9
Current: $15.44
Upside: -41.71%